{"title": "Safety, immunogenicity and duration of protection of a candidate malaria vaccine in Mozambique / Seguridad, inmunogenicidad y duraci\u00f3n de protecci\u00f3n del candidato a vacuna contra la malaria en Mozambique", "author": "Aide; Pedro Carlos Paulino", "url": null, "hostname": null, "description": "Malaria, caused by Plasmodium falciparum parasites remains a huge public health problem and a major cause of morbidity and mortality in sub-Saharan Africa, especially among children and infants. The parasite and its vector \u2013 the Anopheles spp mosquito - have tremendous adaptability capacities, including the acquisition of resistance to anti-malarial drugs and insecticides, making the development of new preventive tools, such as a safe and effective vaccine, a key element to counter balance this tendency. The most advanced malaria vaccine candidate, RTS,S/AS has progressed to a Phase III trial through a research and development plan as a result of an unforeseen partnership between African, European and American research institutions together with GSK Biologicals and the PATH Malaria Vaccine Initiative (MVI). This thesis describes some critical stages of the clinical development plan of this vaccine, reporting clinical trials of the RTS/AS candidate malaria vaccine conducted in Mozambican children and infants. Here we illustrates the assessment of the RTS,S/AS02D safety, humoral and cellular mediated immune responses and the duration of protection over a one year period in infants. We also provide a detailed immunogenicity data of 4 years of follow-up of children aged 1 to 4 years by the time of immunization with RTS,S/AS02A. These studies principally show that the vaccine is safe, well tolerated and highly immunogenic, eliciting both humoral and cell-mediated antibodies. The vaccine also protects children and infants against clinical malaria. Importantly, they also describe for the first time an association between the risk of clinical malaria and Plasmodium falciparum anticircumsporozoite antibody titters. The presented results support the hypothesis that developing a safe, immunogenic and efficacious malaria vaccine is feasible and, together with other studies, they should be the basis for the registry process of what should be the first generation of vaccines against malaria.", "sitename": "Universitat de Barcelona", "date": "2011-09-30", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Alonso, Pedro\n2011-09-30\nB. 40307-2011\n138 p.\nUniversitat de Barcelona. Facultat de Medicina\nMalaria, caused by Plasmodium falciparum parasites remains a huge public health problem and a major cause of morbidity and mortality in sub-Saharan Africa, especially among children and infants. The parasite and its vector \u2013 the Anopheles spp mosquito - have tremendous adaptability capacities, including the acquisition of resistance to anti-malarial drugs and insecticides, making the development of new preventive tools, such as a safe and effective vaccine, a key element to counter balance this tendency. The most advanced malaria vaccine candidate, RTS,S/AS has progressed to a Phase III trial through a research and development plan as a result of an unforeseen partnership between African, European and American research institutions together with GSK Biologicals and the PATH Malaria Vaccine Initiative (MVI). This thesis describes some critical stages of the clinical development plan of this vaccine, reporting clinical trials of the RTS/AS candidate malaria vaccine conducted in Mozambican children and infants. Here we illustrates the assessment of the RTS,S/AS02D safety, humoral and cellular mediated immune responses and the duration of protection over a one year period in infants. We also provide a detailed immunogenicity data of 4 years of follow-up of children aged 1 to 4 years by the time of immunization with RTS,S/AS02A. These studies principally show that the vaccine is safe, well tolerated and highly immunogenic, eliciting both humoral and cell-mediated antibodies. The vaccine also protects children and infants against clinical malaria. Importantly, they also describe for the first time an association between the risk of clinical malaria and Plasmodium falciparum anticircumsporozoite antibody titters. The presented results support the hypothesis that developing a safe, immunogenic and efficacious malaria vaccine is feasible and, together with other studies, they should be the basis for the registry process of what should be the first generation of vaccines against malaria.\nLa malaria, causada por el par\u00e1sito Plasmodium falciparum sigue siendo un gran problema de salud p\u00fablica y una causa importante de mortalidad y morbilidad en el \u00c1frica Sub-Sahariana, especialmente entre los ni\u00f1os y lactantes. El par\u00e1sito y su vector mosquito Anofeles spp. tienen una tremenda capacidad de adaptaci\u00f3n, incluyendo la capacidad de adquirir resistencia a los f\u00e1rmacos antipal\u00fadicos e insecticidas. Es por tanto prioritario desarrollar nuevas herramientas preventivas, entre las cuales una vacuna segura y eficaz, un elemento clave para contrarrestar esta tendencia. La vacuna candidata contra la malaria m\u00e1s avanzada, denominada RTS,S/AS, ha progresado hasta un ensayo de Fase III siguiendo un plan de investigaci\u00f3n y desarrollo cl\u00ednico resultado de una colaboraci\u00f3n sin precedentes entre centros de investigaci\u00f3n Africanos, Europeos y Americanos junto con la GSK Biologicals y PATH Malaria Vaccine Initiative (MVI). Esta tesis describe algunas de las fases cr\u00edticas de estos logros, reportando los ensayos cl\u00ednicos de la vacuna candidata contra la malaria RTS,S/AS llevados a cabo en ni\u00f1os y lactantes de Mozambique. Esta tesis analiza en detalle la evaluaci\u00f3n de la seguridad de esta estrategia, la respuesta inmunol\u00f3gica (tanto humoral como celular) que esta vacuna confiere, y la duraci\u00f3n de la protecci\u00f3n durante un per\u00edodo de seguimiento de un a\u00f1o en los lactantes. Presentamos tambi\u00e9n los datos completos de 4 a\u00f1os de seguimiento de la inmunogenicidad de la RTS,S/AS02A administrada a ni\u00f1os de 1 a 4 a\u00f1os de edad en el momento de su primera vacunaci\u00f3n. Estos estudios demuestran que la vacuna es segura, bien tolerada y altamente inmunog\u00e9nica, produciendo respuestas tanto humorales como celulares. La vacuna tambi\u00e9n protege a los ni\u00f1os y lactantes contra la malaria cl\u00ednica. Adem\u00e1s se describe por primera vez una asociaci\u00f3n entre el riesgo de malaria cl\u00ednica y los niveles de anticuerpos contra la prote\u00edna de circumsporozoito del Plasmodium falciparum. Los resultados aqu\u00ed presentados apoyan la tesis de que el desarrollo de una vacuna eficaz, inmunog\u00e9nica y segura contra la malaria es posible, y deber\u00e1 ser la base, junto con otros estudios, del proceso de registro de la que podr\u00e1 ser la primera generaci\u00f3n de vacunas contra la malaria.\nMal\u00e0ria; Paludismo; Malaria; Vacuna de la mal\u00e0ria; Vacuna de la malaria; Malaria vaccine\n616.9 - Communicable diseases. Infectious and contagious diseases, fevers\nCi\u00e8ncies de la Salut\nADVERTIMENT. L'acc\u00e9s als continguts d'aquesta tesi doctoral i la seva utilitzaci\u00f3 ha de respectar els drets de la persona autora. Pot ser utilitzada per a consulta o estudi personal, aix\u00ed com en activitats o materials d'investigaci\u00f3 i doc\u00e8ncia en els termes establerts a l'art. 32 del Text Ref\u00f3s de la Llei de Propietat Intel\u00b7lectual (RDL 1/1996). Per altres utilitzacions es requereix l'autoritzaci\u00f3 pr\u00e8via i expressa de la persona autora. En qualsevol cas, en la utilitzaci\u00f3 dels seus continguts caldr\u00e0 indicar de forma clara el nom i cognoms de la persona autora i el t\u00edtol de la tesi doctoral. No s'autoritza la seva reproducci\u00f3 o altres formes d'explotaci\u00f3 efectuades amb finalitats de lucre ni la seva comunicaci\u00f3 p\u00fablica des d'un lloc ali\u00e8 al servei TDX. Tampoc s'autoritza la presentaci\u00f3 del seu contingut en una finestra o marc ali\u00e8 a TDX (framing). Aquesta reserva de drets afecta tant als continguts de la tesi com als seus resums i \u00edndexs.", "language": null, "image": null, "pagetype": null, "links": ["/", "/", "/quees", "/contacte", "#", "?locale-attribute=en", "?locale-attribute=ca", "?locale-attribute=es", "/login", "/", "/", "/quees", "/faqs", "/contacte", "#", "?locale-attribute=en", "?locale-attribute=ca", "?locale-attribute=es", "/login", "/", "/handle/10803/1", "/handle/10803/31832", "//www.ub.edu", "", "", null, null, null, "http://www.mendeley.com/import/?url=https://www.tdx.cat/handle/10803/51420", "/bitstream/handle/10803/51420/AIDE_PHD_THESIS.pdf?sequence=1&isAllowed=y", "http://www.tdx.cat/oai/request?verb=GetRecord&metadataPrefix=didl&identifier=oai:www.tdx.cat:10803/51420", "http://www.tdx.cat/oai/request?verb=GetRecord&metadataPrefix=marc&identifier=oai:www.tdx.cat:10803/51420", "http://www.tdx.cat/oai/request?verb=GetRecord&metadataPrefix=marc_ccuc&identifier=oai:www.tdx.cat:10803/51420", "http://www.tdx.cat/oai/request?verb=GetRecord&metadataPrefix=mets&identifier=oai:www.tdx.cat:10803/51420", "http://www.tdx.cat/oai/request?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai:www.tdx.cat:10803/51420", "http://www.tdx.cat/oai/request?verb=GetRecord&metadataPrefix=ore&identifier=oai:www.tdx.cat:10803/51420", "http://www.tdx.cat/oai/request?verb=GetRecord&metadataPrefix=qdc&identifier=oai:www.tdx.cat:10803/51420", "http://www.tdx.cat/oai/request?verb=GetRecord&metadataPrefix=rdf&identifier=oai:www.tdx.cat:10803/51420", "/handle/10803/51420?show=full", "/handle/10803/31832", "/accessibilitat", "/avislegal", "/cookies", "https://confluence.csuc.cat/display/TDX", "/collaborations", "https://www.csuc.cat/"]}